Skip to main content

Table 1 Correlation between patient characteristics, HPV and p16 status

From: Dual role for p16 in the metastasis process of HPV positive head and neck cancers

  HPV negative HPV positive P p16 negative p16 positive P
  No. (%) No. (%)   No. (%) No. (%)  
No. of patients
  175   58    173   68   
Gender      p = 0.67b      p = 0.99b
 Male 146 83 47 81   143 83 56 82  
 Female 29 17 11 19   30 17 12 18  
Age, years     p = 0.031a      p = 0.046a
 Median (Range) 59 (57–60) 61 (59–65)   59 (57–60) 61 (59–64)  
Smoking history     p = 0.001b      p = 0.004b
 Never 8 5 15 26   11 6 13 19  
 Former 20 11 11 19   22 13 11 16  
 Current 126 72 25 43   120 69 35 51  
 Unknown 21 12 7 12   20 12 9 13  
Treatment     p = 0.68b      p = 0.15b
 RT 71 41 19 33   68 39 29 43  
 RT + CT 97 55 34 59   100 58 33 49  
 RT + EGFR inhibitor 5 3 2 3   3 2 4 6  
 Unknown 2 1 3 5   2 1 2 3  
Nodal stage*     p = 0.014b      p = 0.07b
 N0/N1 80 45 16 28   78 45 25 37  
 N2/N3 95 54 42 72   94 54 43 63  
 Unknown 2 1 0 0   1 1 0 0  
Tumor stage*     p = 0.025b      p = 0.11b
 T1/2 51 29 26 45   60 35 22 32  
 T3/4 122 70 31 53   112 65 45 66  
 unknown 2 1 1 2   1 1 1 1  
Disease stage*     p = 0.28b      p = 0.18b
 I-II 17 10 3 5   17 10 3 4  
 III-IV 157 90 54 93   155 90 65 96  
 Unknown 1 1 1 2   1 1 0 0  
HPV           p < 0.0001b
 Negative       150 87 16 24  
 Positive       9 5 44 65  
 Unknown       14 8 8 12  
p16      p < 0.0001b     
 Negative 150 86 9 16       
 Positive 16 9 44 76       
 Unknown 9 5 5 9       
  1. Abbreviations: RT radiotherapy, CT chemotherapy, EGFR epidermal growth factor
  2. *International Union of Cancer Research 1982 classification; aANOVA; bchi square test.